The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64
D. McCarthy(Queen Mary University of London), K A Brown(Uniformed Services University of the Health Sciences), Matthew Streetly(King's College - North Carolina), Stephen Schey(University College Hospital), Marion G. Macey(Royal London Hospital)
Cited by 13
Related Papers
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Prognostic value of thallium-201 myocardial perfusion imaging. A diagnostic tool comes of age.
|Circulation|1991|392
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315